Redesigning oncology clinical trials with agentic AI
Semi-autonomous and autonomous foundation models are helping cancer research and anticancer drug development
Semi-autonomous and autonomous foundation models are helping cancer research and anticancer drug development
Fostering academic clinical research is one of the ESMO’s priorities, and artificial intelligence may be a major driver
A domain-specific natural language processing (NPL) pipeline showed strong performance in extracting clinically meaningful information from diverse clinical documents of patients with non-small cell lung cancer
Mitigating research biases by rigorous data analysis and validation can pave the way for a wider adoption of artificial intelligence in cancer care
In a real-world study, multimodal artificial intelligence models outperform PD-L1 across key endpoints
A study compared the performance of different models using routinely collected clinicopathological data from women with HR-positive/HER2-negative breast cancer
ESMO plays a central role in developing long-lasting recommendations for a safe and effective use of artificial intelligence supporting oncology stakeholders
AI-driven approaches can help to design minibinders, which may bring new T-cell receptor-based therapies closer to the clinic
Can artificial intelligence finally unlock the full potential of cancer genomics? Discover how new digital tools are closing the gap between data and clinical action in oncology.
Computational models can overcome current limitations of 3D analysis of tumour samples
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.